Therapy Detail

Therapy Name KD018
Therapy Description

KD018 is an herbal formulation whose mechanism of action is unclear, but which results in inhibition of CYP3A4, MMP, NF-KB, beta-glucuronidase, and the NK-1 receptor, as well as modulation of certain cytokines, macrophages and lymphocytes (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
KD018 PHY906 KD018 is an herbal formulation whose mechanism of action is unclear, but which results in inhibition of CYP3A4, MMP, NF-KB, beta-glucuronidase, and the NK-1 receptor, as well as modulation of certain cytokines, macrophages and lymphocytes (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02178644 Phase I KD018 Capecitabine Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer Active, not recruiting
NCT00730158 Phase II Irinotecan KD018 A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer Suspended